AstraZeneca Pharma India Ltd Q4 Results
- BSE: 506820
- NSE: ASTRAZEN
- ISIN: INE203A01020
- Sector: Biotechnology & Drugs
BSE
8,550.00
-73.00 (-0.85%)
-73.00 (-0.85%)Volume207.00
Updated: Fri 6 Feb, 2026 | 15:29:02
NSE
8,557.50-64.00 (-0.74%)
-64.00 (-0.74%)Volume4.57 K
Updated: Fri 6 Feb, 2026 | 15:29:33
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Quarter ended Mar 25
Note: Comparison is on QoQ basis
Quarterly - AstraZeneca Pharma India Ltd Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 24 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 417.48 | 405.92 | 2.85% | 337.57 | 23.67% |
| Depreciation/ Amortization | 17.69 | 9.07 | 95.04% | 3.76 | 370.03% |
| Operating Income | 63.00 | 34.37 | 83.30% | 45.63 | 38.07% |
| Net Income | 58.25 | 30.85 | 88.82% | 39.48 | 47.55% |
| Other Operating Expenses Total | 47.35 | 31.33 | 51.13% | 36.96 | 28.12% |
| Net Income Before Taxes | 78.47 | 42.02 | 86.74% | 54.36 | 44.36% |
| Total Revenue | 480.48 | 440.29 | 9.13% | 383.20 | 25.39% |
| Selling/ General/ Admin Expenses Total | 87.15 | 84.94 | 2.60% | 83.30 | 4.62% |
| Diluted Normalized EPS | 25.01 | 22.19 | 12.68% | 15.79 | 58.34% |